SEC Form 4 · accession 0001232524-17-000037
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen L. Smith
Officer — Global Head of R&D and CMO
Period of report
Feb 27, 2017
Accepted (ET)
Mar 1, 2017 · 5:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2 | Feb 27, 2017 | F | 571 | $136.97 | D | 13,668 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
- F2Includes 57 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2016.